Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk-Adapted Stanford V-C With Radiotherapy for Hodgkin's Disease
NCT00026208Phase 2Completed
- Sponsor
- Stanford University
- Start
- Jun 2001
- Primary completion
- Apr 2013
- Modality
- Monoclonal Antibodies, Targeted Liposomes, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of vinblastine, cyclophosphamide, pegylated liposomal doxorubicin, prednisone, vincristine sulfate liposome injection and 2 more in Hodgkin lymphoma (HL) (2 arms), sponsored by Stanford University. Primary endpoint: Progression-free Survival at 3 years. Started Jun 2001; status: completed.
02
Drugs
vinblastinecyclophosphamidepegylated liposomal doxorubicinprednisonevincristine sulfate liposome injection
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00026208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00026208.